Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiovascular Assessment of Ponatinib as Third Line Treatment Option in Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib and Bosutinib (CarPAs)

NCT04709731 is registered in ClinicalTrials.gov with Associazione Italiana Pazienti Leucemia Mieloide Cronica as lead sponsor.

NCT NCT04709731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04709731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiovascular Assessment of Ponatinib as Third Line Treatment Option in Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib and Bosutinib (CarPAs)
Lead sponsor
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2021
Completion date
April 1, 2025
Enrollment
50 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml)